Use of a bioprosthetic mesh in complex hernia repair: early results from a French multicenter pilot study.
BACKGROUND
Implantation of synthetic meshes for reinforcement of abdominal wall hernias can be complicated by mesh infection, which often requires mesh explantation. The risk of mesh infection is increased in a contaminated environment or in patients who have comorbidities such as diabetes or smoking. The use of biological prostheses has been advocated because of their ability to resist infection. Initial results, however, have shown high hernia recurrence rates and wound occurrences. The objective of the present study is to evaluate early and mid-term outcomes in the largest French series that included 43 consecutive complex abdominal hernias repaired with biological prostheses.


METHODS
Retrospective observational study of a prospective collected data bank. Patient demographics, history of previous repairs, intraoperative findings and degree of contamination, associated procedures, postoperative prosthetic-related complications, and long-term results were retrospectively reviewed.


RESULTS
There were 25 (58%) incisional, 14 parastomal, and 4 midline hernia repairs. Hernias were considered "clean" (n = 5), "clean-contaminated" (n = 19), "contaminated" (n = 12), or "dirty" (n = 7). Wound-related morbidity occurred in 17 patients; 4 patients needed reoperation for cutaneous necrosis or abscess. Smoking was the only risk factor associated with wound complication (P = .022). No postoperative wound events required removal of the prosthesis. There were 4 hernia recurrences (9%). A previous attempt at repair (P = .018) and no complete fascia closure (P = .033) were associated with hernia recurrence.


CONCLUSIONS
This study demonstrated that the use of bioprothesis in complex hernia repair allowed successful single-stage reconstruction. Wound-related complications were frequent. Cost-benefit analyses are important to establish the validity of these findings.
Pitié-Salpêtrière Hospital, Paris, France renato.lupinacci@psl.aphp.fr.
Renato Micelli
RM
Lupinacci
Hôpital Avicenne, Bobigny Cedex, France.
Anne Sophie
AS
Gizard
Hôpital Jean Verdier, Paris, France.
Emmanuel
E
Rivkine
Pitié-Salpêtrière Hospital, Paris, France.
Clotilde
C
Debove
Pitié-Salpêtrière Hospital, Paris, France Pierre et Marie Curie University, Paris VI, Paris, France.
Fabrice
F
Menegaux
Hôpital Jean Verdier, Paris, France Paris XIII University, Bobigny, France.
Christophe
C
Barrat
Hôpital Avicenne, Bobigny Cedex, France Paris XIII University, Bobigny, France.
Philippe
P
Wind
Pitié-Salpêtrière Hospital, Paris, France Pierre et Marie Curie University, Paris VI, Paris, France.
Christophe
C
Trésallet
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001705:Bioprosthesis; D005260:Female; D005602:France; D006555:Hernia, Ventral / Q000601:surgery*; D059685:Herniorrhaphy / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011183:Postoperative Complications / Q000209:etiology; D012189:Retrospective Studies; D012307:Risk Factors; D013526:Surgical Mesh; D016896:Treatment Outcome
biological graft; hernia; ventral hernia; xenograft